NO312654B1 - Anvendelse av 8,9-dehydroöstron - Google Patents

Anvendelse av 8,9-dehydroöstron Download PDF

Info

Publication number: NO312654B1
Authority: NO; Norway
Prior art keywords: dehydroestrone; salt; pharmaceutically acceptable; free radical; carbon atoms
Prior art date: 1995-12-04

Application number

NO19965165A

Other languages

English (en)

Norwegian (no)

Other versions

NO965165D0 (no

NO965165L (no

Inventor

Steven Jay Adelman

Original Assignee

Wyeth Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-12-04

Filing date

1996-12-03

Publication date

2002-06-17

1996-12-03 Application filed by Wyeth Corp filed Critical Wyeth Corp

1996-12-03 Publication of NO965165D0 publication Critical patent/NO965165D0/no

1997-06-05 Publication of NO965165L publication Critical patent/NO965165L/no

2002-06-17 Publication of NO312654B1 publication Critical patent/NO312654B1/no

Links

OUGSRCWSHMWPQE-WMZOPIPTSA-N (13s,14s)-3-hydroxy-13-methyl-7,11,12,14,15,16-hexahydro-6h-cyclopenta[a]phenanthren-17-one Chemical compound OC1=CC=C2C(CC[C@]3([C@H]4CCC3=O)C)=C4CCC2=C1 OUGSRCWSHMWPQE-WMZOPIPTSA-N 0.000 title claims description 19
150000003254 radicals Chemical class 0.000 claims description 23
-1 alkali metal salt Chemical class 0.000 claims description 20
230000006378 damage Effects 0.000 claims description 12
125000004432 carbon atom Chemical group C* 0.000 claims description 8
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
150000003839 salts Chemical class 0.000 claims description 8
210000003169 central nervous system Anatomy 0.000 claims description 7
239000012528 membrane Substances 0.000 claims description 7
208000027866 inflammatory disease Diseases 0.000 claims description 6
230000002401 inhibitory effect Effects 0.000 claims description 6
206010039073 rheumatoid arthritis Diseases 0.000 claims description 6
150000002632 lipids Chemical class 0.000 claims description 5
239000000825 pharmaceutical preparation Substances 0.000 claims description 5
208000023275 Autoimmune disease Diseases 0.000 claims description 4
102000004190 Enzymes Human genes 0.000 claims description 4
108090000790 Enzymes Proteins 0.000 claims description 4
102000004310 Ion Channels Human genes 0.000 claims description 4
108090000862 Ion Channels Proteins 0.000 claims description 4
206010028980 Neoplasm Diseases 0.000 claims description 4
101710172711 Structural protein Proteins 0.000 claims description 4
229910052783 alkali metal Inorganic materials 0.000 claims description 4
229910052784 alkaline earth metal Inorganic materials 0.000 claims description 4
125000000217 alkyl group Chemical group 0.000 claims description 4
150000003863 ammonium salts Chemical class 0.000 claims description 4
238000006243 chemical reaction Methods 0.000 claims description 4
125000005265 dialkylamine group Chemical group 0.000 claims description 4
238000004519 manufacturing process Methods 0.000 claims description 4
206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 3
206010008909 Chronic Hepatitis Diseases 0.000 claims description 3
208000000059 Dyspnea Diseases 0.000 claims description 3
206010013975 Dyspnoeas Diseases 0.000 claims description 3
206010014561 Emphysema Diseases 0.000 claims description 3
206010019755 Hepatitis chronic active Diseases 0.000 claims description 3
206010019799 Hepatitis viral Diseases 0.000 claims description 3
201000004681 Psoriasis Diseases 0.000 claims description 3
208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 3
238000011161 development Methods 0.000 claims description 3
238000002360 preparation method Methods 0.000 claims description 3
208000013220 shortness of breath Diseases 0.000 claims description 3
201000000596 systemic lupus erythematosus Diseases 0.000 claims description 3
201000008827 tuberculosis Diseases 0.000 claims description 3
201000001862 viral hepatitis Diseases 0.000 claims description 3
208000001738 Nervous System Trauma Diseases 0.000 claims description 2
208000018262 Peripheral vascular disease Diseases 0.000 claims description 2
208000035475 disorder Diseases 0.000 claims description 2
239000000758 substrate Substances 0.000 claims description 2
229910021653 sulphate ion Inorganic materials 0.000 claims 1
108010007622 LDL Lipoproteins Proteins 0.000 description 13
102000007330 LDL Lipoproteins Human genes 0.000 description 13
239000007788 liquid Substances 0.000 description 12
239000003963 antioxidant agent Substances 0.000 description 11
150000001875 compounds Chemical class 0.000 description 11
239000000203 mixture Substances 0.000 description 11
238000010998 test method Methods 0.000 description 10
239000004480 active ingredient Substances 0.000 description 9
230000015572 biosynthetic process Effects 0.000 description 8
238000000034 method Methods 0.000 description 7
201000010099 disease Diseases 0.000 description 6
230000003647 oxidation Effects 0.000 description 6
238000007254 oxidation reaction Methods 0.000 description 6
230000003078 antioxidant effect Effects 0.000 description 5
210000002540 macrophage Anatomy 0.000 description 5
239000003921 oil Substances 0.000 description 5
230000000144 pharmacologic effect Effects 0.000 description 5
239000007787 solid Substances 0.000 description 5
239000000969 carrier Substances 0.000 description 4
210000004027 cell Anatomy 0.000 description 4
230000005764 inhibitory process Effects 0.000 description 4
230000003859 lipid peroxidation Effects 0.000 description 4
210000004185 liver Anatomy 0.000 description 4
230000001404 mediated effect Effects 0.000 description 4
235000019198 oils Nutrition 0.000 description 4
229910052760 oxygen Inorganic materials 0.000 description 4
239000001301 oxygen Substances 0.000 description 4
230000008569 process Effects 0.000 description 4
DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 3
DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 3
239000000524 Thiobarbituric Acid Reactive Substance Substances 0.000 description 3
238000003556 assay Methods 0.000 description 3
230000001684 chronic effect Effects 0.000 description 3
239000006071 cream Substances 0.000 description 3
239000002552 dosage form Substances 0.000 description 3
239000003937 drug carrier Substances 0.000 description 3
230000000694 effects Effects 0.000 description 3
210000002889 endothelial cell Anatomy 0.000 description 3
229960003399 estrone Drugs 0.000 description 3
210000000224 granular leucocyte Anatomy 0.000 description 3
230000004792 oxidative damage Effects 0.000 description 3
230000001590 oxidative effect Effects 0.000 description 3
108010071584 oxidized low density lipoprotein Proteins 0.000 description 3
238000007911 parenteral administration Methods 0.000 description 3
239000000843 powder Substances 0.000 description 3
239000000243 solution Substances 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
208000024172 Cardiovascular disease Diseases 0.000 description 2
206010061218 Inflammation Diseases 0.000 description 2
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
206010063837 Reperfusion injury Diseases 0.000 description 2
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
230000032683 aging Effects 0.000 description 2
150000001298 alcohols Chemical class 0.000 description 2
210000002403 aortic endothelial cell Anatomy 0.000 description 2
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
239000002775 capsule Substances 0.000 description 2
239000001768 carboxy methyl cellulose Substances 0.000 description 2
230000005779 cell damage Effects 0.000 description 2
230000030833 cell death Effects 0.000 description 2
208000037887 cell injury Diseases 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
235000010980 cellulose Nutrition 0.000 description 2
238000007906 compression Methods 0.000 description 2
230000006835 compression Effects 0.000 description 2
231100000433 cytotoxic Toxicity 0.000 description 2
230000001472 cytotoxic effect Effects 0.000 description 2
230000018109 developmental process Effects 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
239000000796 flavoring agent Substances 0.000 description 2
235000013355 food flavoring agent Nutrition 0.000 description 2
230000004054 inflammatory process Effects 0.000 description 2
208000014674 injury Diseases 0.000 description 2
230000003993 interaction Effects 0.000 description 2
208000028867 ischemia Diseases 0.000 description 2
230000000302 ischemic effect Effects 0.000 description 2
239000000314 lubricant Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
239000002674 ointment Substances 0.000 description 2
239000007800 oxidant agent Substances 0.000 description 2
239000003208 petroleum Substances 0.000 description 2
238000007348 radical reaction Methods 0.000 description 2
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
239000002904 solvent Substances 0.000 description 2
239000008174 sterile solution Substances 0.000 description 2
239000000126 substance Substances 0.000 description 2
239000000375 suspending agent Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
231100000331 toxic Toxicity 0.000 description 2
230000002588 toxic effect Effects 0.000 description 2
HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
208000024827 Alzheimer disease Diseases 0.000 description 1
235000003911 Arachis Nutrition 0.000 description 1
244000105624 Arachis hypogaea Species 0.000 description 1
201000001320 Atherosclerosis Diseases 0.000 description 1
208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
208000020084 Bone disease Diseases 0.000 description 1
206010006187 Breast cancer Diseases 0.000 description 1
208000026310 Breast neoplasm Diseases 0.000 description 1
102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 1
108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 1
229920001353 Dextrin Polymers 0.000 description 1
239000004375 Dextrin Substances 0.000 description 1
LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
WKRLQDKEXYKHJB-UHFFFAOYSA-N Equilin Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3=CCC2=C1 WKRLQDKEXYKHJB-UHFFFAOYSA-N 0.000 description 1
102000008857 Ferritin Human genes 0.000 description 1
108050000784 Ferritin Proteins 0.000 description 1
238000008416 Ferritin Methods 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
206010021143 Hypoxia Diseases 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
102000011965 Lipoprotein Receptors Human genes 0.000 description 1
108010061306 Lipoprotein Receptors Proteins 0.000 description 1
102000004895 Lipoproteins Human genes 0.000 description 1
108090001030 Lipoproteins Proteins 0.000 description 1
206010067125 Liver injury Diseases 0.000 description 1
231100000002 MTT assay Toxicity 0.000 description 1
238000000134 MTT assay Methods 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
208000001132 Osteoporosis Diseases 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
239000002250 absorbent Substances 0.000 description 1
230000002745 absorbent Effects 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
230000004913 activation Effects 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
239000000654 additive Substances 0.000 description 1
208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 1
201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
150000001299 aldehydes Chemical class 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
230000006851 antioxidant defense Effects 0.000 description 1
210000000709 aorta Anatomy 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
206010003246 arthritis Diseases 0.000 description 1
230000000923 atherogenic effect Effects 0.000 description 1
230000008901 benefit Effects 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
230000017531 blood circulation Effects 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
230000000711 cancerogenic effect Effects 0.000 description 1
231100000315 carcinogenic Toxicity 0.000 description 1
230000003915 cell function Effects 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
210000003850 cellular structure Anatomy 0.000 description 1
208000015114 central nervous system disease Diseases 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
231100000481 chemical toxicant Toxicity 0.000 description 1
208000037976 chronic inflammation Diseases 0.000 description 1
208000037893 chronic inflammatory disorder Diseases 0.000 description 1
230000004087 circulation Effects 0.000 description 1
235000019864 coconut oil Nutrition 0.000 description 1
239000003240 coconut oil Substances 0.000 description 1
239000003086 colorant Substances 0.000 description 1
231100000135 cytotoxicity Toxicity 0.000 description 1
230000003013 cytotoxicity Effects 0.000 description 1
230000007423 decrease Effects 0.000 description 1
235000019425 dextrin Nutrition 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
210000003038 endothelium Anatomy 0.000 description 1
WKRLQDKEXYKHJB-HFTRVMKXSA-N equilin Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4C3=CCC2=C1 WKRLQDKEXYKHJB-HFTRVMKXSA-N 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
229960005309 estradiol Drugs 0.000 description 1
LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
229940093471 ethyl oleate Drugs 0.000 description 1
230000003090 exacerbative effect Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000003925 fat Substances 0.000 description 1
235000019197 fats Nutrition 0.000 description 1
239000000945 filler Substances 0.000 description 1
210000000497 foam cell Anatomy 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
238000009472 formulation Methods 0.000 description 1
230000002538 fungal effect Effects 0.000 description 1
239000000499 gel Substances 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
150000002334 glycols Chemical class 0.000 description 1
150000008282 halocarbons Chemical class 0.000 description 1
230000005802 health problem Effects 0.000 description 1
231100000234 hepatic damage Toxicity 0.000 description 1
TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical compound [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 description 1
230000001146 hypoxic effect Effects 0.000 description 1
238000011534 incubation Methods 0.000 description 1
229910052738 indium Inorganic materials 0.000 description 1
230000028709 inflammatory response Effects 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
239000000543 intermediate Substances 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
239000007928 intraperitoneal injection Substances 0.000 description 1
239000003456 ion exchange resin Substances 0.000 description 1
229920003303 ion-exchange polymer Polymers 0.000 description 1
229910052742 iron Inorganic materials 0.000 description 1
239000008101 lactose Substances 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
230000003902 lesion Effects 0.000 description 1
230000008818 liver damage Effects 0.000 description 1
208000019423 liver disease Diseases 0.000 description 1
239000006210 lotion Substances 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
239000000463 material Substances 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
210000004165 myocardium Anatomy 0.000 description 1
210000000440 neutrophil Anatomy 0.000 description 1
210000000633 nuclear envelope Anatomy 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
239000012057 packaged powder Substances 0.000 description 1
239000006072 paste Substances 0.000 description 1
230000036285 pathological change Effects 0.000 description 1
231100000915 pathological change Toxicity 0.000 description 1
238000005502 peroxidation Methods 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002265 prevention Effects 0.000 description 1
239000003380 propellant Substances 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
230000022558 protein metabolic process Effects 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
239000002516 radical scavenger Substances 0.000 description 1
238000012552 review Methods 0.000 description 1
102000014452 scavenger receptors Human genes 0.000 description 1
108010078070 scavenger receptors Proteins 0.000 description 1
239000008247 solid mixture Substances 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
150000005846 sugar alcohols Polymers 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
239000000829 suppository Substances 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
239000007885 tablet disintegrant Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
239000002562 thickening agent Substances 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
239000003440 toxic substance Substances 0.000 description 1
230000008733 trauma Effects 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
208000019553 vascular disease Diseases 0.000 description 1
239000001993 wax Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Immunology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Gastroenterology & Hepatology (AREA)
Dermatology (AREA)
Pulmonology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Transplantation (AREA)
Neurology (AREA)
Virology (AREA)
Biochemistry (AREA)
Toxicology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Plural Heterocyclic Compounds (AREA)
Hydrogenated Pyridines (AREA)
Steroid Compounds (AREA)

NO19965165A 1995-12-04 1996-12-03 Anvendelse av 8,9-dehydroöstron NO312654B1 (no)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US793195P	1995-12-04	1995-12-04

Publications (3)

Publication Number	Publication Date
NO965165D0 NO965165D0 (no)	1996-12-03
NO965165L NO965165L (no)	1997-06-05
NO312654B1 true NO312654B1 (no)	2002-06-17

Family

ID=21728885

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO19965165A NO312654B1 (no)	1995-12-04	1996-12-03	Anvendelse av 8,9-dehydroöstron

Country Status (22)

Country	Link
EP (1)	EP0778025B1 (de)
JP (1)	JPH09169650A (de)
KR (1)	KR100444002B1 (de)
CN (1)	CN1104900C (de)
AR (2)	AR005866A1 (de)
AT (1)	ATE263565T1 (de)
AU (1)	AU703814B2 (de)
BR (1)	BR9605777A (de)
CA (1)	CA2191835A1 (de)
CZ (1)	CZ289780B6 (de)
DE (1)	DE69632117T2 (de)
DK (1)	DK0778025T3 (de)
ES (1)	ES2215187T3 (de)
HU (1)	HUP9603329A3 (de)
IL (1)	IL119744A (de)
MX (1)	MX9606009A (de)
NO (1)	NO312654B1 (de)
NZ (1)	NZ299858A (de)
PT (1)	PT778025E (de)
SI (1)	SI0778025T1 (de)
SK (1)	SK154296A3 (de)
ZA (1)	ZA969923B (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE19723794A1 (de) *	1997-06-06	1998-12-10	Jenapharm Gmbh	Nichtestrogene Derivate des Estradiols mit antioxidativer Aktivität
JP2002322081A (ja) *	2001-02-22	2002-11-08	Nonogawa Shoji Kk	生体の遺伝子損傷抑制剤
US7892751B2 (en)	2003-06-09	2011-02-22	Redox-Reactive Reagents Llc	Method of detecting or diagnosing of a neurodegenerative disease or condition
US9557325B2 (en)	2003-06-09	2017-01-31	Redox-Reactive Reagents Llc	Method of altering the binding specificity of proteins by oxidation-reduction reactions
AU2004248155B2 (en) *	2003-06-09	2008-10-23	Redox-Reactive Reagents L.L.C.	Method of altering the binding specificity of plasma proteins by oxidation-reduction reactions

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5210081A (en) *	1992-02-26	1993-05-11	American Home Products Corporation	Alkali metal 8,9-dehydroestrone sulfate esters
DE4334823C2 (de) *	1993-10-09	1998-09-17	Schering Ag	Verfahren zur Herstellung von Schwefelsäurehalbestern von Estrogenen
US5395831A (en) *	1994-04-08	1995-03-07	American Home Products Corporation	Treating cardiac disorders with Δ9(11)-dehydro-8-isoestrone
DE19509729A1 (de) *	1995-03-13	1996-09-19	Schering Ag	17-Difluormethylen-Estratriene

1996
- 1996-11-25 AU AU71944/96A patent/AU703814B2/en not_active Ceased
- 1996-11-26 ZA ZA9609923A patent/ZA969923B/xx unknown
- 1996-11-27 AR ARP960105366A patent/AR005866A1/es not_active Application Discontinuation
- 1996-11-28 DK DK96308632T patent/DK0778025T3/da active
- 1996-11-28 EP EP96308632A patent/EP0778025B1/de not_active Expired - Lifetime
- 1996-11-28 SI SI9630674T patent/SI0778025T1/xx unknown
- 1996-11-28 AT AT96308632T patent/ATE263565T1/de not_active IP Right Cessation
- 1996-11-28 PT PT96308632T patent/PT778025E/pt unknown
- 1996-11-28 ES ES96308632T patent/ES2215187T3/es not_active Expired - Lifetime
- 1996-11-28 DE DE69632117T patent/DE69632117T2/de not_active Expired - Fee Related
- 1996-12-02 MX MX9606009A patent/MX9606009A/es not_active IP Right Cessation
- 1996-12-02 SK SK1542-96A patent/SK154296A3/sk unknown
- 1996-12-02 BR BR9605777A patent/BR9605777A/pt not_active Application Discontinuation
- 1996-12-02 CA CA002191835A patent/CA2191835A1/en not_active Abandoned
- 1996-12-02 NZ NZ299858A patent/NZ299858A/en unknown
- 1996-12-03 CZ CZ19963532A patent/CZ289780B6/cs not_active IP Right Cessation
- 1996-12-03 JP JP8322539A patent/JPH09169650A/ja not_active Ceased
- 1996-12-03 IL IL11974496A patent/IL119744A/xx not_active IP Right Cessation
- 1996-12-03 HU HU9603329A patent/HUP9603329A3/hu unknown
- 1996-12-03 NO NO19965165A patent/NO312654B1/no unknown
- 1996-12-03 KR KR1019960061345A patent/KR100444002B1/ko not_active Expired - Fee Related
- 1996-12-03 CN CN96123342A patent/CN1104900C/zh not_active Expired - Fee Related
2007
- 2007-03-19 AR ARP070101105A patent/AR059965A2/es not_active Application Discontinuation

Also Published As

Publication number	Publication date
HUP9603329A2 (en)	1997-08-28
NO965165D0 (no)	1996-12-03
AU703814B2 (en)	1999-04-01
MX9606009A (es)	1997-08-30
DE69632117D1 (de)	2004-05-13
KR970032870A (ko)	1997-07-22
HU9603329D0 (en)	1997-01-28
SI0778025T1 (en)	2004-08-31
NO965165L (no)	1997-06-05
CN1158725A (zh)	1997-09-10
HUP9603329A3 (en)	1998-01-28
DK0778025T3 (da)	2004-06-07
AU7194496A (en)	1997-06-12
EP0778025A1 (de)	1997-06-11
ATE263565T1 (de)	2004-04-15
AR059965A2 (es)	2008-05-14
PT778025E (pt)	2004-08-31
IL119744A (en)	2003-01-12
CA2191835A1 (en)	1997-06-05
AR005866A1 (es)	1999-07-21
ZA969923B (en)	1998-05-26
BR9605777A (pt)	1998-08-25
EP0778025B1 (de)	2004-04-07
HK1010095A1 (en)	1999-06-11
CN1104900C (zh)	2003-04-09
KR100444002B1 (ko)	2004-11-03
CZ289780B6 (cs)	2002-04-17
IL119744A0 (en)	1997-03-18
NZ299858A (en)	2001-03-30
ES2215187T3 (es)	2004-10-01
SK154296A3 (en)	1997-08-06
JPH09169650A (ja)	1997-06-30
DE69632117T2 (de)	2004-08-26
CZ353296A3 (en)	1997-08-13

Publication	Publication Date	Title
DK165839B (da)	1993-01-25	Tigogenin-cellobiosidforbindelser, farmaceutiske praeparater, der indeholder forbindelserne, anvendelse af forbindelserne til fremstilling af et farmaceutisk praeparat samt fremgangsmaade til fremstilling af forbindelserne
NO312654B1 (no)	2002-06-17	Anvendelse av 8,9-dehydroöstron
AU743586B2 (en)	2002-01-31	Use of equilenin as an antioxidant
MXPA96006009A (en)	1997-08-01	Use of 8,9-dehydroestrone as an antioxide
AU743519B2 (en)	2002-01-31	17alpha-dihydroequilenin for use as a medical antioxidant
AU744098C (en)	2003-07-31	Use of 17beta-dihydroequilenin as an antioxidant
US6271221B1 (en)	2001-08-07	Use of equilenin as an antioxidant
US7022688B1 (en)	2006-04-04	Use of 17β-dihydroequilenin as an antioxidant
HK1010095B (en)	2005-01-14	Use of 8, 9-dehydroestrone for the manufacture of a medicament for the treatment of diseases caused by free radicals
EP1513862A2 (de)	2005-03-16	Neue derivate von androstan und androsten mit ascorbinsäure und deren verwendung zur behandlung bzw. prävention verschiedener leiden, krankheiten und störungen
USRE37999E1 (en)	2003-02-18	20-(B)-20,25-dihydroperoxy-3β-hydroxycholest-5-ene and 20-(S)-20,25-dihydroperoxy-3β-hydroxycholest-5-ene
CA2335361A1 (en)	1999-12-23	Medicament for reducing side effects of adrenocortical hormones
HK1025514A (en)	2000-11-17	5-alpha-pregnan-3-beta-ol-20-one sulfate for the treatment of tumours and cns diseases
HK1025514B (en)	2003-01-30	5-alpha-pregnan-3-beta-ol-20-one sulfate for the treatment of tumours and cns diseases